WHO Regional Office for Europe Antimicrobial Medicines Consumption (AMC) Network AMC data 2011–2014 WHO Regional Office for Europe Antimicrobial Medicines Consumption (AMC) Network AMC data 2011–2014 Abstract This report sets out and analyses data on antimicrobial medicines consumption (AMC) collected from non-European Union countries in the WHO European Region and Kosovo (in accordance with Security Council resolution 1244 (1999)). Its aims are to support countries that are building or strengthening their national surveillance systems on AMC and to stimulate the sharing of data both within and between countries. The WHO Regional Office for Europe and its partners remain committed to supporting countries in these endeavours through the activities of the WHO AMC Network. Keywords ANTIMICROBIAL MEDICINES CONSUMPTION NATIONAL SURVEILLANCE NETWORKS ANTI-INFECTIVE AGENTS – THERAPEUTIC USE DRUG RESISTANCE, MICROBIAL EPIDEMIOLOGICAL MONITORING DATA COLLECTION EUROPE Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest). ISBN: 9789289052382 © World Health Organization 2017 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization. CONTENTS Acknowledgements. vi Foreword. ix Abbreviations . .x Summary . xi 1. Introduction . 1 2. The WHO Antimicrobial Medicines Consumption (AMC) Network. 2 2.1 Background. 2 2.2 Objectives of the WHO AMC Network. 3 2.3 Participating countries and areas . 4 3. Data collection and analysis . 5 3.1 Methodology. .5 3.2 Data collection. .6 3.3 Data analysis. .7 3.4 Data interpretation. 10 4. Albania . 12 4.1 Data sources and years of data collection. 12 4.2 Estimates of volumes of consumption of J01 anti-infective agents. 12 4.3 Relative consumption of J01 anti-infective agents by subgroup. 14 4.4 Relative consumption by choice of agent. 16 4.5 The 10 most consumed agents . 20 4.6 Comments. 21 5. Armenia . 22 5.1 Data sources and years of data collection. 22 5.2 Estimates of volumes of consumption of J01 anti-infective agents. 22 5.3 Relative consumption of J01 anti-infective agents by subgroup. 24 5.4 Relative consumption by choice of agent. 27 5.5 The 10 most consumed agents . 30 5.6 Comments. 31 6. Azerbaijan . 32 6.1 Data sources and years of data collection. 32 6.2 Estimates of volumes of consumption of J01 anti-infective agents. 32 6.3 Relative consumption of J01 anti-infective agents by subgroup. 34 6.4 Relative consumption by choice of agent. 36 iii 6.5 The 10 most consumed agents . 39 6.6 Comments. 41 7. Belarus . 42 7.1 Data sources and years of data collection. 42 7.2 Estimates of volumes of consumption of J01 anti-infective agents. 42 7.3 Relative consumption of J01 anti-infective agents by subgroup. 44 7.4 Relative consumption by choice of agent. 46 7.5 The 10 most consumed agents . 50 7.6 Comments. 51 8. Kyrgyzstan. 52 8.1 Data sources and years of data collection. 52 8.2 Estimates of volumes of consumption of J01 anti-infective agents. 52 8.3 Relative consumption of J01 anti-infective agents by subgroup. 55 8.4 Relative consumption by choice of agent. 57 8.5 The 10 most consumed agents . 60 8.6 Comments. 61 9. Montenegro . 62 9.1 Data sources and years of data collection. 62 9.2 Estimates of volumes of consumption of J01 anti-infective agents. 62 9.3 Relative consumption of J01 anti-infective agents by subgroup. 64 9.4 Relative consumption by choice of agent. 66 9.5 The 10 most consumed agents . 69 9.6 Comments. 71 10. Republic of Moldova . 72 10.1 Data sources and years of data collection. 72 10.2 Estimates of volumes of consumption of J01 anti-infective agents. 72 10.3 Relative consumption of J01 anti-infective agents by subgroup . 75 10.4 Relative consumption by choice of agent. 77 10.5 The 10 most consumed agents . 80 10.6 Comments . 81 11. Serbia . ..